{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,7,30]],"date-time":"2025-07-30T16:15:53Z","timestamp":1753892153597,"version":"3.41.2"},"reference-count":48,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T00:00:00Z","timestamp":1642464000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pharmacol."],"abstract":"<jats:p><jats:bold>Objective:<\/jats:bold> This study assessed the efficacy, acceptability, and safety of pharmaceutical management for combat-related post-traumatic stress disorder (PTSD) to provide a clinical decision-making basis for clinicians.<\/jats:p><jats:p><jats:bold>Method:<\/jats:bold> A comprehensive search was conducted using Ovid MEDLINE, Ovid EMBASE, Cochrane Library, Scopus, ScienceDirect, and Web of Science for randomized controlled trails (RCTs), which reported pharmaceutical management and placobo for adults with combat-related PTSD, that were published until April 21, 2021. The effectiveness, acceptability, and adverse events (AEs), were designed as interested outcomes. The change in total symptoms of combat-related PTSD according to the clinician rating scale was defined as primary outcome, and the others were defined as secondary outcomes.<\/jats:p><jats:p><jats:bold>Results:<\/jats:bold> Twenty-two RCTs with 1,221 patients were involved. Compared with placebo, overall active comparators had statistical differences for all outcomes, including the change in total symptoms of combat-related PTSD [SMD = \u22120.36, 95%CI (\u22120.62,\u22120.09)], depression [SMD = \u22120.28, 95%CI (\u22120.45,\u22120.10)], anxiety [SMD = \u22120.44, 95%CI (\u22120.64,\u22120.23)], re-experience [SMD = \u22120.33, 95%CI (\u22120.52,\u22120.13)], avoidance [SMD = \u22120.24, 95%CI (\u22120.43,\u22120.05)], and hyper-arousal [SMD = \u22120.26, 95%CI (\u22120.48,\u22120.03)]. Compared with the placebo, in terms of acceptability, overall active comparators did not significantly decrease all-cause discontinuance rates [RR = 0.97, 95%CI (0.78,1.20)], and the significance decreased due to AEs [RR = 2.42, 95%CI (1.41,4.13)]. Nevertheless, overall there was no statistically significant difference for overall AEs, including somnolence, sedation, dizziness, paresthesia, anxiety, blurred vision, generalized anxiety disorder, and sleep disturbance. All funnel plots were symmetrical and no publication bias was found.<\/jats:p><jats:p><jats:bold>Conclusion:<\/jats:bold> Active drugs, especially amitriptyline, imipramine, and quetiapine, had a positive effect on the improvement of combat-related PTSD symptoms. Despite there being no significant increase in the AEs of the active drugs, the fact that the discontinuation rates of these drugs, including risperidone, imipramine, and topiramate, were increased deserves attention. Furthermore, as active drugs were effective across ethnic groups and battlefields, active drug regimens were revealed to be more appropriate for treating people with symptoms of extreme severe PTSD (\u226580) or PTSD that is at least 8\u00a0weeks old. In addition, current evidence was from adults under 60\u00a0years of age and male combat-related PTSD. Whether this evidence can be extended to other populations of combat-related PTSD needs to be confirmed by subsequent high-quality, large-sample studies.<\/jats:p>","DOI":"10.3389\/fphar.2021.805354","type":"journal-article","created":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T06:55:50Z","timestamp":1642488950000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Effectiveness, Acceptability and Safety of Pharmaceutical Management for Combat-Related PTSD in Adults Based on Systematic Review of Twenty-Two Randomized Controlled Trials"],"prefix":"10.3389","volume":"12","author":[{"given":"Jin-Zhu","family":"Yan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Jia-Ling","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiao-Zheng","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Zhi-Xin","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Run-Ben","family":"Liu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chao","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Qin-Qin","family":"Gong","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,1,18]]},"reference":[{"key":"B1","doi-asserted-by":"crossref","first-page":"838","DOI":"10.1016\/B978-0-12-386454-3.00796-X","article-title":"Tricyclic Antidepressants","volume-title":"Encyclopedia of Toxicology","author":"Abdollahi","year":"2014"},{"key":"B2","doi-asserted-by":"publisher","first-page":"240","DOI":"10.1186\/1744-859x-5-s1-s225","article-title":"The Comparison of Topiramate and Placebo in the Treatment of Posttraumatic Stress Disorder: A Randomized, Double- Blind Study","volume":"5","author":"Akuchekian","year":"2004","journal-title":"J. Res. Med. Sci."},{"key":"B3","doi-asserted-by":"publisher","first-page":"240","DOI":"10.3109\/10673229.2011.614483","article-title":"The Psychopharmacology Algorithm Project at the Harvard South Shore Program: an Update on Posttraumatic Stress Disorder","volume":"19","author":"Bajor","year":"2011","journal-title":"Harv. Rev. Psychiatry"},{"key":"B4","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1097\/01.pra.0000456590.12998.41","article-title":"Effect of Pregabalin Augmentation in Treatment of Patients with Combat-Related Chronic Posttraumatic Stress Disorder: a Randomized Controlled Trial","volume":"20","author":"Baniasadi","year":"2014","journal-title":"J. Psychiatr. Pract."},{"key":"B5","doi-asserted-by":"publisher","first-page":"474","DOI":"10.1016\/j.biopsych.2004.11.039","article-title":"Adjunctive Risperidone in the Treatment of Chronic Combat-Related Posttraumatic Stress Disorder","volume":"57","author":"Bartzokis","year":"2005","journal-title":"Biol. Psychiatry"},{"key":"B6","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/jts.22421","article-title":"The International Society for Traumatic Stress Studies New Guidelines for the Prevention and Treatment of Posttraumatic Stress Disorder: Methodology and Development Process","volume":"32","author":"Bisson","year":"2019","journal-title":"J. Trauma Stress"},{"key":"B7","doi-asserted-by":"publisher","first-page":"155","DOI":"10.1111\/bph.13346","article-title":"Quetiapine and its Metabolite Norquetiapine: Translation from In Vitro Pharmacology to In Vivo Efficacy in Rodent Models","volume":"173","author":"Cross","year":"2016","journal-title":"Br. J. Pharmacol."},{"key":"B8","doi-asserted-by":"publisher","first-page":"259","DOI":"10.1001\/archpsyc.1990.01810150059010","article-title":"Treatment of Posttraumatic Stress Disorder with Amitriptyline and Placebo","volume":"47","author":"Davidson","year":"1990","journal-title":"Arch. Gen. Psychiatry"},{"key":"B9","first-page":"8","article-title":"A Placebo-Controlled Trial of Guanfacine for the Treatment of Posttraumatic Stress Disorder in Veterans","volume":"41","author":"Davis","year":"2008","journal-title":"Psychopharmacol. Bull."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2888","DOI":"10.3390\/ijms19102888","article-title":"Eradicating Suicide at its Roots: Preclinical Bases and Clinical Evidence of the Efficacy of Ketamine in the Treatment of Suicidal Behaviors","volume":"19","author":"De Berardis","year":"2018","journal-title":"Int. J. Mol. Sci."},{"key":"B11","article-title":"Imipramine Therapy and CYP2D6 and CYP2C19 Genotype","volume-title":"Medical Genetics Summaries","author":"Dean","year":"2012"},{"volume-title":"Guideline Post-traumatic Stress Disorder","year":"2019","key":"B12"},{"key":"B13","doi-asserted-by":"publisher","first-page":"1306","DOI":"10.1001\/archinte.164.12.1306","article-title":"Burden of Medical Illness in Women with Depression and Posttraumatic Stress Disorder","volume":"164","author":"Frayne","year":"2004","journal-title":"Arch. Intern. Med."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1097\/00004850-200301000-00001","article-title":"Adjunctive Risperidone Treatment in post-traumatic Stress Disorder: a Preliminary Controlled Trial of Effects on Comorbid Psychotic Symptoms","volume":"18","author":"Hamner","year":"2003","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B15","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1023\/a:1009076231175","article-title":"Lack of Efficacy for Fluoxetine in PTSD: a Placebo Controlled Trial in Combat Veterans","volume":"12","author":"Hertzberg","year":"2000","journal-title":"Ann. Clin. Psychiatry"},{"key":"B16","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1136\/bmj.327.7414.557","article-title":"Measuring Inconsistency in Meta-Analyses","volume":"327","author":"Higgins","year":"2003","journal-title":"BMJ"},{"volume-title":"Cochrane Handbook for Systematic Reviews of Interventions","year":"2011","author":"Julian","key":"B17"},{"key":"B18","doi-asserted-by":"publisher","first-page":"169","DOI":"10.1002\/mpr.1359","article-title":"Twelve-month and Lifetime Prevalence and Lifetime Morbid Risk of Anxiety and Mood Disorders in the United States","volume":"21","author":"Kessler","year":"2012","journal-title":"Int. J. Methods Psychiatr. Res."},{"key":"B19","first-page":"4","article-title":"Posttraumatic Stress Disorder: the burden to the Individual and to Society","volume":"61","author":"Kessler","year":"2000","journal-title":"J. Clin. Psychiatry"},{"key":"B20","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1001\/archpsyc.1995.03950240066012","article-title":"Posttraumatic Stress Disorder in the National Comorbidity Survey","volume":"52","author":"Kessler","year":"1995","journal-title":"Arch. Gen. Psychiatry"},{"key":"B21","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/00005053-199106000-00011","article-title":"Pharmacotherapy for Posttraumatic Stress Disorder Using Phenelzine or Imipramine","volume":"179","author":"Kosten","year":"1991","journal-title":"J. Nerv Ment. Dis."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1080\/13811110903478997","article-title":"Post-traumatic Stress Disorder and Suicide Risk: a Systematic Review","volume":"14","author":"Krysinska","year":"2010","journal-title":"Arch. Suicide Res."},{"key":"B23","doi-asserted-by":"publisher","first-page":"677","DOI":"10.1097\/jcp.0b013e31815a43ee","article-title":"A Randomized, Double-Blind, Placebo-Controlled Trial of Augmentation Topiramate for Chronic Combat-Related Posttraumatic Stress Disorder","volume":"27","author":"Lindley","year":"2007","journal-title":"J. Clin. Psychopharmacol."},{"key":"B24","doi-asserted-by":"publisher","DOI":"10.1111\/cpsp.12006","article-title":"Posttraumatic Stress Disorder and Co-occurring Substance Use Disorders: Advances in Assessment and Treatment","volume":"19","author":"McCauley","year":"2012","journal-title":"Clin. Psychol. (N.Y): A Publication Division Clin. Psychol. Am. Psychol. Assoc."},{"key":"B25","doi-asserted-by":"publisher","first-page":"595","DOI":"10.4088\/JCP.12r07757","article-title":"Patient Preference for Psychological vs Pharmacologic Treatment of Psychiatric Disorders: a Meta-Analytic Review","volume":"74","author":"McHugh","year":"2013","journal-title":"J. Clin. Psychiatry"},{"key":"B26","doi-asserted-by":"publisher","first-page":"486","DOI":"10.1016\/S2215-0366(18)30135-4","article-title":"3,4-methylenedioxymethamphetamine (MDMA)-assisted Psychotherapy for post-traumatic Stress Disorder in Military Veterans, Firefighters, and Police Officers: a Randomised, Double-Blind, Dose-Response, Phase 2 Clinical Trial","volume":"5","author":"Mithoefer","year":"2018","journal-title":"Lancet Psychiatry"},{"key":"B27","doi-asserted-by":"publisher","first-page":"959","DOI":"10.4088\/jcp.v69n0611","article-title":"Pharmacotherapy of PTSD in the U.S. Department of Veterans Affairs: Diagnostic- and Symptom-Guided Drug Selection","volume":"69","author":"Mohamed","year":"2008","journal-title":"J. Clin. Psychiatry"},{"key":"B28","doi-asserted-by":"publisher","first-page":"b2535","DOI":"10.1136\/bmj.b2535","article-title":"Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA Statement","volume":"339","author":"Moher","year":"2009","journal-title":"BMJ"},{"key":"B29","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1097\/00004714-200304000-00012","article-title":"Low-dose Risperidone as Adjunctive Therapy for Irritable Aggression in Posttraumatic Stress Disorder","volume":"23","author":"Monnelly","year":"2003","journal-title":"J. Clin. Psychopharmacol."},{"key":"B30","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1097\/YIC.0000000000000061","article-title":"A Pilot Randomized Placebo-Controlled Trial of Adjunctive Aripiprazole for Chronic PTSD in US Military Veterans Resistant to Antidepressant Treatment","volume":"30","author":"Naylor","year":"2015","journal-title":"Int. Clin. Psychopharmacol."},{"key":"B31","doi-asserted-by":"publisher","first-page":"2186","DOI":"10.1176\/appi.ajp.163.12.2186","article-title":"No Improvement of Posttraumatic Stress Disorder Symptoms with Guanfacine Treatment","volume":"163","author":"Neylan","year":"2006","journal-title":"Am. J. Psychiatry"},{"key":"B32","doi-asserted-by":"publisher","first-page":"20m13714","DOI":"10.4088\/JCP.20m13714","article-title":"Prevalence, Correlates, and Treatment of Suicidal Behavior in US Military Veterans: Results from the 2019-2020 National Health and Resilience in Veterans Study","volume":"82","author":"Nichter","year":"2021","journal-title":"J. Clin. Psychiatry"},{"key":"B33","doi-asserted-by":"publisher","first-page":"207","DOI":"10.30773\/pi.2019.0171","article-title":"Understanding the Complex of Suicide in Depression: from Research to Clinics","volume":"17","author":"Orsolini","year":"2020","journal-title":"Psychiatry Investig."},{"key":"B34","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1111\/acer.12926","article-title":"Prazosin for Veterans with Posttraumatic Stress Disorder and Comorbid Alcohol Dependence: A Clinical Trial","volume":"40","author":"Petrakis","year":"2016","journal-title":"Alcohol. Clin. Exp. Res."},{"key":"B35","doi-asserted-by":"publisher","first-page":"e0126529","DOI":"10.1371\/journal.pone.0126529","article-title":"Effects of Pharmacotherapy on Combat-Related PTSD, Anxiety, and Depression: A Systematic Review and Meta-Regression Analysis","volume":"10","author":"Puetz","year":"2015","journal-title":"PloS one"},{"key":"B36","doi-asserted-by":"publisher","first-page":"17m02138","DOI":"10.4088\/PCC.17m02138","article-title":"A Double-Blind, Placebo-Controlled Randomized Trial of Vilazodone in the Treatment of Posttraumatic Stress Disorder and Comorbid Depression","volume":"19","author":"Ramaswamy","year":"2017","journal-title":"Prim. Care Companion CNS Disord."},{"key":"B37","doi-asserted-by":"publisher","first-page":"507","DOI":"10.1056\/NEJMoa1507598","article-title":"Trial of Prazosin for Post-Traumatic Stress Disorder in Military Veterans","volume":"378","author":"Raskind","year":"2018","journal-title":"N. Engl. J. Med."},{"key":"B38","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1016\/j.biopsych.2006.06.032","article-title":"A Parallel Group Placebo Controlled Study of Prazosin for Trauma Nightmares and Sleep Disturbance in Combat Veterans with post-traumatic Stress Disorder","volume":"61","author":"Raskind","year":"2007","journal-title":"Biol. Psychiatry"},{"key":"B39","first-page":"623","article-title":"PTSD Treatment for Veterans: What's Working, What's New, and What's Next","volume":"41","author":"Reisman","year":"2016","journal-title":"P T"},{"key":"B40","doi-asserted-by":"publisher","first-page":"54","DOI":"10.1097\/JCP.0000000000000624","article-title":"Effect of Rivastigmine Augmentation in Treatment of Male Patients with Combat-Related Chronic Posttraumatic Stress Disorder: A Randomized Controlled Trial","volume":"37","author":"Rezaei Ardani","year":"2017","journal-title":"J. Clin. Psychopharmacol."},{"key":"B41","doi-asserted-by":"publisher","first-page":"20m13233","DOI":"10.4088\/JCP.20m13233","article-title":"Randomized Controlled Trial of Riluzole Augmentation for Posttraumatic Stress Disorder: Efficacy of a Glutamatergic Modulator for Antidepressant-Resistant Symptoms","volume":"81","author":"Spangler","year":"2020","journal-title":"J. Clin. Psychiatry"},{"key":"B42","doi-asserted-by":"publisher","first-page":"1777","DOI":"10.1176\/appi.ajp.159.10.1777","article-title":"Adjunctive Olanzapine for SSRI-Resistant Combat-Related PTSD: a Double-Blind, Placebo-Controlled Study","volume":"159","author":"Stein","year":"2002","journal-title":"Am. J. Psychiatry"},{"key":"B43","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1080\/00332747.2017.1286892","article-title":"Facilitating Fear-Based Memory Extinction with Dexamethasone: A Randomized Controlled Trial in Male Veterans with Combat-Related PTSD","volume":"80","author":"Sur\u00eds","year":"2017","journal-title":"Psychiatry"},{"key":"B44","doi-asserted-by":"publisher","first-page":"827","DOI":"10.2147\/DDDT.S63779","article-title":"Quetiapine for Acute Bipolar Depression: a Systematic Review and Meta-Analysis","volume":"8","author":"Suttajit","year":"2014","journal-title":"Drug Des. Devel Ther."},{"key":"B45","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1176\/appi.focus.16408","article-title":"VA\/DOD Clinical Practice Guideline for the Management of Posttraumatic Stress Disorder and Acute Stress Disorder: Clinician Summary","volume":"16","year":"2018","journal-title":"Focus (American Psychiatric Publishing)"},{"key":"B46","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1176\/appi.ajp.2016.15070967","article-title":"Efficacy of Quetiapine Monotherapy in Posttraumatic Stress Disorder: A Randomized, Placebo-Controlled Trial","volume":"173","author":"Villarreal","year":"2016","journal-title":"Am. J. Psychiatry"},{"key":"B47","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1016\/j.euroneuro.2011.07.018","article-title":"The Size and burden of Mental Disorders and Other Disorders of the Brain in Europe 2010","volume":"21","author":"Wittchen","year":"2011","journal-title":"Eur. Neuropsychopharmacol."},{"key":"B48","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1176\/appi.ajp.2018.17090995","article-title":"Doubly Randomized Preference Trial of Prolonged Exposure versus Sertraline for Treatment of PTSD","volume":"176","author":"Zoellner","year":"2019","journal-title":"Am. J. Psychiatry"}],"container-title":["Frontiers in Pharmacology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.805354\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,1,18]],"date-time":"2022-01-18T06:55:57Z","timestamp":1642488957000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fphar.2021.805354\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,1,18]]},"references-count":48,"alternative-id":["10.3389\/fphar.2021.805354"],"URL":"https:\/\/doi.org\/10.3389\/fphar.2021.805354","relation":{},"ISSN":["1663-9812"],"issn-type":[{"type":"electronic","value":"1663-9812"}],"subject":[],"published":{"date-parts":[[2022,1,18]]},"article-number":"805354"}}